City
Epaper

After Vij tests COVID positive, Bharat Biotech says COVAXIN efficacy can be determined only 14 days after second dose

By ANI | Updated: December 5, 2020 15:15 IST

After Haryana Home Minister Anil Vij tested positive for the COVID-19 despite taking a shot of Bharat Biotech's vaccine candidate around two weeks ago, the company clarified on Saturday that its efficacy can only be determined 14 days after the second dose.

Open in App

After Haryana Home Minister l Vij tested positive for the COVID-19 despite taking a shot of Bharat Biotech's vaccine candidate around two weeks ago, the company clarified on Saturday that its efficacy can only be determined 14 days after the second dose.

The Haryana home minister was administered the first dose of Bharat biotech vaccine candidate, COVAXIN, around two weeks ago, during its ongoing Phase-III trials.

"COVAXIN clinical trials are based on a two-dose schedule, given 28 days apart. The vaccine efficacy will be determined 14 days after the second dose. COVAXIN has been designed to be efficacious when subjects receive both the doses," Bharat Biotech said in a statement.

Earlier today, Vij tweeted that he has tested positive for the coronavirus and is admitted to Civil Hospital in Ambala.

"I have been tested Corona positive. I am admitted to Civil Hospital Ambala Cantt. All those who have come in close contact with me are advised to get themselves tested for corona," the Minister tweeted.

Bharat Biotech added the Phase-III trials are double-blinded and randomised, where 50 per cent of subjects will receive the vaccine and 50 per cent will receive placebo.

"As per CDSCO-DCGI guidelines for reporting adverse events, patients are required to contact the site Principle Investigator (PI) during active follow up, or when the PI determines the severity of the adverse effect; then the reports are to be submitted to site Ethics Committees, CDSCO-DCGI, Data Safety Monitoring Board and the sponsor," the biotech company said.

On November 20, Vij was administered the first trial dose of Bharat Biotech's COVAXIN, a fully indigenously developed COVID-19 vaccine candidate, in Haryana.

Bharat Biotech is conducting the largest Phase-III clinical trials in India. The goal is to evaluate the efficacy of COVAXIN across India and determine its suitability to the diverse Indian population.

( With inputs from ANI )

Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

Open in App

Related Stories

Other SportsWomen’s World Cup: ‘Perfect Strike’ as Amit Shah, former players hail India’s big win over Pakistan

NationalNortheast Frontier Railway records 9.63 per cent rise in freight unloading

Other SportsPKL 12: Bengaluru Bulls earn revenge over Tamil Thalaivas, seal 33-29 win in thriller

Other SportsHosting World Para Athletics Championships successfully gives India pride of place globally, say top stars, legends

Other SportsIrani Cup: Winning each time has a different feeling, says Akshay Wadkar as Vidarbha lift title

National Realted Stories

NationalFive killed in Chhattisgarh road accident

NationalHagrama Mohilary sworn in as BTC chief; possible BPF-BJP alliance on the horizon

NationalDurga Puja festivities conclude in Bengal with spectacular carnival in Kolkata

NationalZubeen Garg death probe: CM Sarma warns members of Assam Association in Singapore

NationalAssam Rifles defuses two powerful IEDs in Manipur’s Jiribam averting major incident